Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

ABSTRACT: SNB-101 is a novel nano-particle formulation of SN-38, the active metabolite of irinotecan(CPT-11). Study SNB101P01 is a multicenter, open-label, dose escalation, phase 1 study of SNB 101 with its active ingredient SN-38, in participants with advanced solid tumors. Dose escalation will occur using a modified accelerated titration design (ATD). All participants will receive SNB 101 in different cohorts. SNB 101 will be administered intravenously to participants on day 1 and day 15 of each 28 day treatment cycle until progressive disease, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first. A Safety Review Committee will determine dose escalation, de-escalation, and modification and the MTD/RP2D based on DLTs and other safety information.

DISEASE(S): Ovarian Cancer,Pancreas Cancer,Gastric Cancer,Colorectal Cancer,Small Cell Lung Carcinoma,Head And Neck Cancer,Small-cell Lung Cancer,Pancreatic Neoplasms,Breast Cancer,Solid Tumors

PROVIDER: 2358597 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR